Breaking News Instant updates and real-time market news.

KTWO

K2M Group

$23.88

-0.77 (-3.12%)

, WMGI

Wright Medical

$26.88

-1.49 (-5.25%)

08:32
07/31/17
07/31
08:32
07/31/17
08:32

K2M Group, Wright Medical have 'favorable set-up' into results, says RBC Capital

RBC Capital analyst Glenn Novarro says that the decline of K2M (KTWO) and Wight Medical (WMGI) in sympathy with NuVasive (NUVA) has created a "favorable set-up" in the first two names heading into their Q2 results. The analyst says that in-line results by K2M and Wright Medical should lead to "relief rallies" by the stocks.

KTWO

K2M Group

$23.88

-0.77 (-3.12%)

WMGI

Wright Medical

$26.88

-1.49 (-5.25%)

NUVA

NuVasive

$67.11

-9.79 (-12.73%)

  • 01

    Aug

  • 02

    Aug

  • 15

    Aug

  • 21

    Aug

KTWO K2M Group
$23.88

-0.77 (-3.12%)

03/24/17
PIPR
03/24/17
NO CHANGE
Target $25
PIPR
Overweight
Piper calls K2M Group a 'must-own name at these levels'
Piper Jaffray analyst Matt O'Brien views K2M Group shares a "must-own name at these levels." After hosting meetings with management, the analyst believes the company's guidance for the year is conservative. K2M is well ahead of the competition in 3D printing, the analyst contends. He keeps an Overweight rating on the shares with a $25 price target.
04/07/17
COWN
04/07/17
NO CHANGE
Target $26
COWN
Outperform
K2M Group price target raised to $26 from $21 at Cowen
Cowen analyst Joshua Jennings raised his price target on K2M Group to $26 from $21 citing its consistent 2016 performance and expectations for consistent sustainable revenue growth into the future. The analyst said K2M Group is a uniquely positioned, innovative player in a consolidating spine market and at current valuation he remains a buyer. Jennings reiterated his Outperform rating on K2M group shares.
04/24/17
LEHM
04/24/17
DOWNGRADE
Target $32
LEHM
Equal Weight
Mazor Robotics downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Matthew Taylor downgraded Mazor Robotics (MZOR) to Equal Weight citing valuation following the recent rally in the shares. The analyst raised his price target for the stock to $32 from $31. Taylor this morning also downgraded Globus Medical (GMED) to Underweight after surveying 51 U.S. spine surgeons. He views the survey as positive for NuVasive (NUVA), K2M Group (KTWO) and Medtronic (MDT).
05/16/17
PIPR
05/16/17
NO CHANGE
Target $25
PIPR
Overweight
K2M Group shares remain under-owned, says Piper Jaffray
After visiting the company's headquarters, Piper Jaffray analyst Matt O'Brien says K2M Group remains his favorite name in the space. He continues to believe the story is underappreciated and the shares are under-owned. The analyst highlights K2M's progress in Japan and Australia and keeps an Overweight rating on the stock with a $25 price target.
WMGI Wright Medical
$26.88

-1.49 (-5.25%)

05/04/17
RBCM
05/04/17
NO CHANGE
RBCM
Wright Medical should be bought on any weakness,says RBC Capital
After Wright Medical reported lower than expected revenue, RBC Capital analyst Glenn Novarro blames the miss on "sales force distraction and realignment in U.S. lower extremities." He expects these issues to be transitory and recommends buying the stock on any weakness.
06/29/17
CANT
06/29/17
INITIATION
Target $33
CANT
Overweight
Wright Medical initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Travis Steed started Wright Medical with an Overweight rating and $33 price target.
05/04/17
BMOC
05/04/17
NO CHANGE
BMOC
Wright Medical outlook still attractive despite Q1 miss, says BMO Capital
After Wright Medical reported weaker than expected Q1 results, BMO Capital analyst Joanne Wuensch notes that the company reiterated its full year guidance. She continues to view Wright as "a consolidation candidate" and raised her price target on the shares to $34 from $31 while keeping an Outperform rating on the stock.
04/11/17
BOFA
04/11/17
DOWNGRADE
Target $32
BOFA
Neutral
Wright Medical downgraded to Neutral on valuation at BofA/Merrill
BofA/Merrill analyst Bob Hopkins downgraded Wright Medical to Neutral from Buy citing valuation and maintained a $32 price target on shares.
NUVA NuVasive
$67.11

-9.79 (-12.73%)

07/28/17
PIPR
07/28/17
NO CHANGE
Target $90
PIPR
Overweight
NuVasive selloff brings buying opportunity, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien recommends investors use the post-earnings selloff today in shares of NuVasive as a buying opportunity. While the slightly below expectations Q2, resignation of CFO Quentin Blackford, the Office of Inspector General subpoena and comments on heightened pricing pressure are "startling," the wheels are not coming off at NuVasive and the revenue headwinds as temporary, O'Brien tells investors in a research note. He does not believe the OIG matter "materializes into something too problematic." The analyst keeps an Overweight rating on the shares with a $90 price target.
07/28/17
BARD
07/28/17
DOWNGRADE
BARD
Neutral
NuVasive downgraded to Neutral from Outperform at Baird
07/31/17
RBCM
07/31/17
NO CHANGE
RBCM
NuVasive weakness overdone, says RBC Capital
After NuVasive reported lower than expected revenue and two seniors managers left the company, contributing to a roughly 14% decline in the stock Friday, RBC Capital analyst Glenn Novarro says that the weakness was overdone. He says that the market is concerned about the U.S. spine market, but he believes that the stock's decline was overdone and he recommends that investors buy the stock at current levels. The analyst does not believe that the managers' departure indicates that the company is losing momentum, and he thinks that its new products will enable it to gain share. Finally, he thinks that the stock's valuation now reflects the "bear case".on the U.S. spine market, and he recommends buying the shares at current levels.
07/05/17
PIPR
07/05/17
NO CHANGE
Target $90
PIPR
Overweight
NuVasive's LessRay an underappreciated growth driver, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien views NuVasive's LessRay technology, which can reduce surgical radiation exposure by up to 90%, as an underappreciated growth driver for the company. The market size for LessRay is around $500M in the U.S. alone, a figure that increases as NuVasive adds more features to the system in the coming years, O'Brien tells investors in a research note. The analyst "conservatively" estimate the company will generate around $10M in sales from this technology next year. He encourages investors to start or build positions in NuVasive. O'Brien has an Overweight rating in the shares with a $90 price target.

TODAY'S FREE FLY STORIES

15:05
08/17/17
08/17
15:05
08/17/17
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

EPD

Enterprise Products

$25.07

-0.1 (-0.40%)

15:00
08/17/17
08/17
15:00
08/17/17
15:00
Options
Put buyers in Energy Products Partners »

Put buyers in Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LB

L Brands

$36.84

-2.11 (-5.42%)

14:58
08/17/17
08/17
14:58
08/17/17
14:58
Recommendations
L Brands analyst commentary  »

L Brands not in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

NUE

Nucor

$54.75

-1.98 (-3.49%)

14:58
08/17/17
08/17
14:58
08/17/17
14:58
Syndicate
Breaking Syndicate news story on Nucor »

Nucor files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$29.21

0.03 (0.10%)

, TSRO

Tesaro

$112.99

-1.01 (-0.89%)

14:50
08/17/17
08/17
14:50
08/17/17
14:50
Recommendations
AstraZeneca, Tesaro, Clovis analyst commentary  »

Lynparza labeling could…

AZN

AstraZeneca

$29.21

0.03 (0.10%)

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

CLVS

Clovis

$71.77

-0.11 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

GOOG

Alphabet

$926.96

4.74 (0.51%)

, GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

14:50
08/17/17
08/17
14:50
08/17/17
14:50
Periodicals
Google piloting data-friendly Search app in Indonesia, TechCrunch reports »

Google is pilot testing a…

GOOG

Alphabet

$926.96

4.74 (0.51%)

GOOGL

Alphabet Class A

$944.27

6.19 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Aug

  • 24

    Aug

AMAT

Applied Materials

$44.46

0.58 (1.32%)

14:49
08/17/17
08/17
14:49
08/17/17
14:49
Options
Applied Materials options imply 6.9% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

AZN

AstraZeneca

$29.17

-0.015 (-0.05%)

, CLVS

Clovis

$71.77

-0.11 (-0.15%)

14:44
08/17/17
08/17
14:44
08/17/17
14:44
Hot Stocks
Feuerstein says Lynparza approval shows FDA sees no differences in PARPs »

STAT's Adam…

AZN

AstraZeneca

$29.17

-0.015 (-0.05%)

CLVS

Clovis

$71.77

-0.11 (-0.15%)

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

FSM

Fortuna Silver Mines

$4.49

-0.01 (-0.22%)

14:30
08/17/17
08/17
14:30
08/17/17
14:30
Options
6.5K Fortuna Silver Mines Aug - Sep 4 call spreads for 9c »

6.5K Fortuna Silver Mines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:30
08/17/17
08/17
14:30
08/17/17
14:30
General news
NY Fed's Survey of Primary Dealers showed expectations for December hike »

NY Fed's Survey of…

PCLN

Priceline

$1,855.72

-5.115 (-0.27%)

14:26
08/17/17
08/17
14:26
08/17/17
14:26
Recommendations
Priceline analyst commentary  »

Priceline recent pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAH

Platform Specialty Products

$12.21

-0.345 (-2.75%)

14:25
08/17/17
08/17
14:25
08/17/17
14:25
Options
Platform Specialty Products call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:25
08/17/17
08/17
14:25
08/17/17
14:25
General news
Canada CPI Preview »

Canada CPI Preview:…

TLSYY

Telstra

$17.11

0.585 (3.54%)

14:23
08/17/17
08/17
14:23
08/17/17
14:23
Downgrade
Telstra rating change  »

Telstra downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$57.49

-0.785 (-1.35%)

, XLI

Industrial Select Sector SPDR

$67.77

-0.84 (-1.22%)

14:23
08/17/17
08/17
14:23
08/17/17
14:23
Technical Analysis
Technical View: S&P 500 breaks another support layer »

The S&P 500 (SPX) is…

XLK

Technology Select Sector SPDR

$57.49

-0.785 (-1.35%)

XLI

Industrial Select Sector SPDR

$67.77

-0.84 (-1.22%)

XLY

Consumer Discretionary Sector SPDR

$89.23

-0.9 (-1.00%)

XLF

Financial Select Sector

$24.78

-0.26 (-1.04%)

SPY

SPDR S&P 500 ETF Trust

$244.48

-2.465 (-1.00%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$111.10

-0.48 (-0.43%)

14:18
08/17/17
08/17
14:18
08/17/17
14:18
Hot Stocks
ADP says Pershing presentation contains nothing not already analyzed »

ADP issued a statement in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

$NSD

NASDAQ Market Internals

14:17
08/17/17
08/17
14:17
08/17/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GT

Goodyear Tire

$30.29

-0.01 (-0.03%)

14:16
08/17/17
08/17
14:16
08/17/17
14:16
Hot Stocks
Goodyear Tire names Christopher Helsel Chief Technology Officer »

The Goodyear Tire &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
08/17/17
08/17
14:16
08/17/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USB

U.S. Bancorp

$52.02

-0.83 (-1.57%)

14:15
08/17/17
08/17
14:15
08/17/17
14:15
Options
US Bancorp put volume heavy and directionally bearish »

Bearish flow noted in US…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 18

    Oct

  • 17

    Jan

14:10
08/17/17
08/17
14:10
08/17/17
14:10
General news
Fed dove Kashkari said Fed would consider the debt ceiling »

Fed dove Kashkari said…

AVGO

Broadcom

$253.42

-0.27 (-0.11%)

, CSCO

Cisco

$32.34

0.25 (0.78%)

14:08
08/17/17
08/17
14:08
08/17/17
14:08
Hot Stocks
FTC approves final order on Broadcom's acquisition of Brocade »

Following a public…

AVGO

Broadcom

$253.42

-0.27 (-0.11%)

CSCO

Cisco

$32.34

0.25 (0.78%)

BRCD

Brocade

$12.24

0.03 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

  • 24

    Aug

  • 06

    Sep

TXMD

TherapeuticsMD

$6.31

0.3718 (6.26%)

14:05
08/17/17
08/17
14:05
08/17/17
14:05
Options
TherapeuticsMD call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

14:02
08/17/17
08/17
14:02
08/17/17
14:02
General news
Trump condemns terror attack in Barcelona, says 'we love you' »

President Trump just…

PFE

Pfizer

$33.13

-0.235 (-0.70%)

14:02
08/17/17
08/17
14:02
08/17/17
14:02
Hot Stocks
Pfizer receives FDA approval for Besponsa for ALL treatment »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 08

    Sep

  • 08

    Sep

  • 13

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.